| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 280.05 | 10.0% |
| Total Income | 280.05 | 10.0% |
| Expenditure | 237.43 | 11.8% |
| PBT | 42.61 | 387.5% |
| Net Profit | 26.59 | 300.5% |
| OPM | — | |
| NPM | 9.49% | 14.70pp |
| EPS | 0.09 | 280.0% |
Sotera Health: Q1 2026 Net Revenues Up 10.0% to $280.045 Million
05 May 2026 · 5 May, 4:47 pm
Summary
Sotera Health Company reported a strong start to 2026, with Q1 net revenues increasing by 10.0% to $280.045 million. Net income improved significantly to $27 million, or $0.09 per diluted share, compared to a net loss in the prior year. The company's Adjusted EBITDA also saw a 10.5% increase. Based on the first-quarter performance, Sotera Health reaffirmed its full-year 2026 outlook, projecting continued growth in net revenues and Adjusted EBITDA.
Key Highlights
- 1
Sotera Health's Q1 2026 net revenues increased by 10.0% compared to Q1 2025, reaching $280.045 million.
- 2
Net income for Q1 2026 was $27 million, or $0.09 per diluted share, a significant improvement from the net loss of $13 million in Q1 2025.
- 3
Adjusted EBITDA for Q1 2026 increased by 10.5% compared to the prior year.
- 4
Adjusted EPS for Q1 2026 was $0.18, representing a 29% increase per diluted share.
- 5
Sterigenics' Q1 2026 net revenues increased by 9.7% to $186 million.
- 6
Nordion's Q1 2026 net revenues were up 29.0% to $42 million.
- 7
The company reaffirmed its full-year 2026 outlook, projecting net revenues growth of 5.0% - 6.5% and Adjusted EBITDA growth of 5.5% - 7.0%, both on a constant currency basis.
Management Comments
Michael B. Petras
Jr.
"We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion." "Growth was driven by disciplined execution at Sterigenics and Nordion, and Nelson Labs came in as we outlined on our fourth-quarter 2025 earnings call. Based on our first-quarter performance, we are reaffirming our 2026 outlook and remain confident in our trajectory for the remainder of the year." "In addition to adding Rich Kyle to our Board of Directors in February, we are also excited to welcome Ken Krause, who joined our Board in March. Ken’s leadership and proven track record of creating shareholder value as a public company chief financial officer for over 10 years, and his extensive experience in strategy, finance and governance will be tremendous assets as we continue to grow."
Informational and educational content only. Not investment advice.